U.S. flag

An official website of the United States government

NM_022041.4(GAN):c.944C>T (p.Pro315Leu) AND Inborn genetic diseases

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jan 18, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002374390.3

Allele description [Variation Report for NM_022041.4(GAN):c.944C>T (p.Pro315Leu)]

NM_022041.4(GAN):c.944C>T (p.Pro315Leu)

Gene:
GAN:gigaxonin [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
16q23.2
Genomic location:
Preferred name:
NM_022041.4(GAN):c.944C>T (p.Pro315Leu)
HGVS:
  • NC_000016.10:g.81357902C>T
  • NG_009007.1:g.47937C>T
  • NM_001377486.1:c.305C>T
  • NM_022041.4:c.944C>TMANE SELECT
  • NP_001364415.1:p.Pro102Leu
  • NP_071324.1:p.Pro315Leu
  • NP_071324.1:p.Pro315Leu
  • LRG_242t1:c.944C>T
  • LRG_242:g.47937C>T
  • LRG_242p1:p.Pro315Leu
  • NC_000016.9:g.81391507C>T
  • NM_022041.3:c.944C>T
  • Q9H2C0:p.Pro315Leu
Protein change:
P102L
Links:
UniProtKB: Q9H2C0#VAR_054116; dbSNP: rs144486241
NCBI 1000 Genomes Browser:
rs144486241
Molecular consequence:
  • NM_001377486.1:c.305C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_022041.4:c.944C>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Inborn genetic diseases
Identifiers:
MeSH: D030342; MedGen: C0950123

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002684644Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Uncertain significance
(Jan 18, 2022)
germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Clinical and molecular findings in patients with giant axonal neuropathy (GAN).

Bruno C, Bertini E, Federico A, Tonoli E, Lispi ML, Cassandrini D, Pedemonte M, Santorelli FM, Filocamo M, Dotti MT, Schenone A, Malandrini A, Minetti C.

Neurology. 2004 Jan 13;62(1):13-6.

PubMed [citation]
PMID:
14718689

New mutations, genotype phenotype studies and manifesting carriers in giant axonal neuropathy.

Houlden H, Groves M, Miedzybrodzka Z, Roper H, Willis T, Winer J, Cole G, Reilly MM.

J Neurol Neurosurg Psychiatry. 2007 Nov;78(11):1267-70. Epub 2007 Jun 19.

PubMed [citation]
PMID:
17578852
PMCID:
PMC2117591

Details of each submission

From Ambry Genetics, SCV002684644.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

The p.P315L variant (also known as c.944C>T), located in coding exon 5 of the GAN gene, results from a C to T substitution at nucleotide position 944. The proline at codon 315 is replaced by leucine, an amino acid with similar properties. In one individual with giant axonal neuropathy, this alteration was detected in trans with a frameshift alteration in GAN (Houlden H et al. J Neurol Neurosurg Psychiatry, 2007 Nov;78:1267-70). This alteration was also detected as compound heterozygous with a missense alteration in GAN In another individual with giant axonal neuropathy; however, the phase of the variants was unknown (Bruno C et al. Neurology, 2004 Jan;62:13-6). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024